Spero Therapeutics (SPRO) Insider Tregoning Buys 10,000 Shares

Insider Kathleen Tregoning bought 10,000 shares of Spero Therapeutics, Inc. (SPRO) on June 23, 2026. The purchase was valued at around $20,200 based on a share price of $2.02 at the time. This transaction reflects increasing confidence among insiders at the company as they navigate the biotechnology sector focused on treating multi-drug resistant infections.

Inside Kathleen Tregoning's Trade

Kathleen Tregoning's acquisition adds to a larger trend at Spero Therapeutics, which has seen multiple insiders purchase shares. On the same day, Frank Thomas purchased 20,000 shares, while Vink Patrick V.J.J. and Cynthia Smith also bought 20,000 and 10,000 shares respectively. These transactions suggest a strong belief in the potential of Spero's product candidates, which include treatments for complicated urinary tract infections.

Other Institutional Activity in Spero Therapeutics

Several notable funds hold shares in Spero Therapeutics. Vanguard Capital Management LLC increased its stake by 236,327 shares, bringing its total to 2,036,226 shares valued at approximately $2.26 million. Meanwhile, Renaissance Technologies, LLC reduced its position, selling off 241,287 shares to end up with 947,904 shares worth about $1.05 million. Other institutions like GSK plc and Pfizer Inc. maintained their holdings, with no significant share changes reported.

Spero Therapeutics, Inc. Stock Up 78.8%

As of the publication date, Spero Therapeutics shares traded at $2.02, showing an increase from the previous close of $1.13. The stock has experienced a 52-week range between $1.08 and $3.08, indicating that it is currently closer to its recent highs. The company's market capitalization stands at about $66.4 million, hinting at its relatively small size in the biotechnology sector.

Recent Earnings

In its most recent earnings report, Spero Therapeutics reported revenue of approximately $46.9 million, with a net margin of about 15.71%. The company is expected to report its next earnings on November 12, 2026, providing insights into its ongoing performance and strategy in the competitive healthcare market.

Analysts Set New Price Targets

On September 14, 2026, HC Wainwright & Co. maintained a Buy rating on Spero Therapeutics, raising the price target from $5.00 to $6.00. This aligns with a positive sentiment around the company's future growth and development of its product pipeline, supported by recent insider activity.

About Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, MA. It focuses on developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its key product candidate is an oral antibiotic aimed at treating complicated urinary tract infections, which has completed important clinical trials. This insider trading activity may reflect confidence in the company’s potential advancements.

Bottom Line

With multiple insiders buying shares, Spero Therapeutics is seeing significant confidence from those closely involved with the company. Investors should keep an eye on upcoming earnings and further insider transactions as the company continues to develop its promising treatments. Remember, this insider trading reflects past holdings and may not represent current positions.